De Novo Mutations And The Pathogenesis Of Childhood-onset Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,406,510.00
Summary
This project aims to reveal the gene abnormalities that cause devastating autoimmune diseases to develop in some children, such as Type 1 diabetes, juvenile arthritis and autoimmune destruction of blood cells. The project will use new technologies to identify alterations in the DNA sequence of a child compared to either of their parents, and to test suspicious DNA alterations in laboratory mice in order to understand the gene effects and evaluate new treatments.
Special Research Initiatives - Grant ID: SR140100001
Funder
Australian Research Council
Funding Amount
$35,000,000.00
Summary
The Juvenile Diabetes Research Foundation Australian Type 1 Diabetes Research Network and Program. This Proposal continues the development of the initial Type 1 Diabetes Clinical Research Network (CRN), launched by JDRF in June 2011 with a $5m grant from the Australian Government.
The principal goal of the CRN is to positively impact the life of people with T1D in Australia through the support and promotion of clinical research. A further electoral commitment of $35m over 5 years will enable f ....The Juvenile Diabetes Research Foundation Australian Type 1 Diabetes Research Network and Program. This Proposal continues the development of the initial Type 1 Diabetes Clinical Research Network (CRN), launched by JDRF in June 2011 with a $5m grant from the Australian Government.
The principal goal of the CRN is to positively impact the life of people with T1D in Australia through the support and promotion of clinical research. A further electoral commitment of $35m over 5 years will enable further progress towards finding a cure for T1D, including delivering better and faster access to new therapies and treatments that can help prevent and manage the disease.
Read moreRead less
Gene therapy for islet transplantation. Improved understanding of aetiology of type I diabetes. Development of islet transplantation as a clinical therapeutic for type I diabetes. Improved efficacy of islet transplantation. Improved health for subjects with type I diabetes. Decreased diabetic complications. Improved quality of life for subjects with type I diabetes. Reduced burden on health system for management of diabetic complications for subjects with type I diabetes